drugset / Trial / NCT04032080
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer.
Timeline
- Start
- 2019-09-05
- Primary completion
- 2022-06-01
- Completion
- 2022-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prexasertib | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Samotolisib | Small molecule | 150 mg | Oral |